Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.

Although the OS and DFS data are immature due to the relatively short follow-up duration, the data in our study showed a trend toward long-term survival benefit which is comparable to previously reported studies.

also in 53,322 other papers